cilostazol has been researched along with bucladesine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Hagiwara, M; Hidaka, H; Ishikawa, T; Itoh, H; Onoda, K; Tanaka, T | 1 |
| Onaya, T; Shindo, H; Tawata, M | 1 |
| Hidaka, H; Kashiwagi, A; Kikkawa, R; Nishio, Y; Takahara, N | 1 |
| Hong, KW; Kim, CD; Kim, KY; Kim, MJ; Lee, JH; Lee, WS; Park, SY | 1 |
| Hayashi, A; Ono, N; Takeya, H; Taniguchi, M; Yakura, Y | 1 |
6 other study(ies) available for cilostazol and bucladesine
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta, Thoracic; Azoles; Bucladesine; Calcium; Cilostazol; Colforsin; Cyclic AMP; Cyclic GMP; In Vitro Techniques; Muscle Contraction; Muscle, Smooth, Vascular; Rabbits; Tetrazoles; Vasodilator Agents | 1988 |
Cyclic adenosine 3',5'-monophosphate enhances sodium, potassium-adenosine triphosphatase activity in the sciatic nerve of streptozotocin-induced diabetic rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Bucladesine; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Iloprost; In Vitro Techniques; Inositol; Kinetics; Male; Myelin Sheath; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reference Values; Sciatic Nerve; Sodium-Potassium-Exchanging ATPase; Tetrazoles | 1993 |
Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Bucladesine; Cells, Cultured; Chemokine CCL2; Cilostazol; Cyclic AMP; Endothelium, Vascular; Humans; NF-kappa B; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; RNA, Messenger; Tetrazoles; Tumor Necrosis Factor-alpha; Umbilical Veins | 1997 |
Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Bucladesine; Cell Line; Cilostazol; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; DNA Fragmentation; Endothelial Cells; Enzyme Activation; Humans; Lipopolysaccharides; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tetrazoles; Tumor Necrosis Factor-alpha | 2006 |
Effect of dibutyryl cyclic adenosine monophosphate on the gene expression of plasminogen activator inhibitor-1 and tissue factor in adipocytes.
Topics: 3T3-L1 Cells; Adenylyl Cyclases; Adipocytes; Adrenergic beta-Agonists; Animals; Bucladesine; Cilostazol; Colforsin; Cyclic AMP; Enzyme Activation; Enzyme Activators; Gene Expression Regulation; Hypertrophy; Isoproterenol; Lipid Metabolism; Mice; Phosphodiesterase Inhibitors; Plasminogen Activator Inhibitor 1; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thromboplastin | 2011 |